Europe RNAi Therapeutics Market Size, Share, and Analysis by 2027

The Europe RNAi therapeutics market is expected to reach US$ 324.33 million in 2027 from US$ 170.42 million in 2019. The market is estimated to grow with a CAGR of 8.4% from 2020-2027.

The growing investments in RNAi therapies and rising prevalence of infectious diseases & chronic conditions in Europe are the key factors driving the growth of RNAi therapeutics. However, high cost of RNAi therapies is the major factor hindering the market growth in Europe.

RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes which are responsible for diseases. Currently, the awareness about RNAi is increasing extensively due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development. Increasing number of investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the Europe RNAi Therapeutics market during the forecast period.

According to the WHO, more than 15 million people are currently living with at least one chronic disease in UK. This has propelled the growth of healthcare systems. Extensive R&D activities are being conducted by government institutions and academic research centers to discover new drug delivery technologies and deal with the increasing number of patients suffering from infectious diseases (e.g., pneumonia, meningitis, food poisoning, and flu) and chronic conditions (e.g., cancer, diabetes, and cardiovascular conditions).

Carbapenem-resistant Enterobacteriaceae and, in particular, those with carbapenemases, are an emerging infection problem in a major paediatric hospital in the UK. According to British Lung Foundation, in 2012, 345 people for every 100,000 people had pneumonia. Unfortunately, in the period 2001–10, 214 people for every million died from pneumonia in the UK. Most of the people affected by pneumonia are adults. These numbers show that the cases of infectious diseases, especially caused due to bacteria, are increasing day by day. Furthermore, cancer and diabetes are among the leading causes of mortality. According to Cancer Research UK, in between 2015-2017, there are around 367,000 new cancer cases in the UK every year, that's around 1,000 every day. RNAi therapies have significant potential to provide promising treatment for such extensively increasing diseases. Thus, the staggering number of cases necessitates the need for superior treatments, which, in turn, bolsters the growth of the RNAi therapeutics market.

In Europe there is exponential growth of COVID-19 cases. Spain, Italy, Germany, France, and the UK are among the most affected European countries. Growing research activities to develop treatment against COVID-19 is likely to favor the growth of the market. In June 2020, the scientists from University of Oxford have been testing existing drugs as therapies for the new infection. Thus, growing focus on development of therapies against corona virus is likely to favor the growth of the market in the Europe.

Rest of Europe RNAi Therapeutics Market, Revenue and Forecast to 2027 (US$ Mn)

EUROPE RNAi THERAPEUTICS MARKET SEGMENTATION

By Molecule Type

• Small Interfering RNAs (siRNA)
• MicroRNA (miRNA)

By Route of Administration

• Pulmonary Delivery
• Intravenous Injections
• Intradermal Injections
• Intraperitoneal Injections
• Others

By Application

• Oncology
• Cardiovascular
• Respiratory Disorders
• Renal Diseases
• Genetic Disorders
• Neurodegenerative Disorders
• Infectious Diseases
• Others

By End User

• Research and Academic Laboratories
• Hospitals
• Diagnostic Laboratories

By Country

• Germany
• UK
• France
• Italy
• Spain

Company Profiles

• Alnylam Pharmaceuticals, Inc
• Sanofi
• GlaxoSmithKline plc
• Silence Therapeutics
• Arrowhead Pharmaceuticals, Inc

Europe RNAi Therapeutics Report Scope